Recursion Pharmaceuticals, Inc. (Recursion), a biotechnology firm trading under the ticker RXRX, has reported an initial statement of beneficial ownership of securities filed by director Najat Khan. The SEC Form 3, filed on April 23, 2024, indicates that Khan does not beneficially own any securities in the company. The form, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, was submitted following an event on April 16, 2024. The document was signed by Jonathan Golightly, attorney-in-fact, and confirms Khan's status as a director and a 10% owner of the issuer. This filing is part of the regulatory requirements that track the ownership of securities by corporate insiders, providing transparency for investors regarding the holdings of key company officials.

Recursion Pharmaceuticals, Inc. (Recursion), a biotechnology firm trading under the ticker RXRX, has reported an initial statement of beneficial ownership of securities filed by director Najat Khan. The SEC Form 3, filed on April 23, 2024, indicates that Khan does not beneficially own any securities in the company. The form, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, was submitted following an event on April 16, 2024. The document was signed by Jonathan Golightly, attorney-in-fact, and confirms Khan's status as a director and a 10% owner of the issuer. This filing is part of the regulatory requirements that track the ownership of securities by corporate insiders, providing transparency for investors regarding the holdings of key company officials.